Latest filing published 12 Feb 2024 for ImmunoGen, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Theresa Wingrove, listed as senior executive, appears in our data through filings on ImmunoGen, Inc. shares, published by SEC (Form 4). We count 42 filings; the first trade dates from 10 January 2014 and the latest from 12 February 2024.
Every open-market trade on record is a sale: 13 sales worth €21.4M. Outside the open market, there are 11 share grants and 17 option exercises. 2024 to date brings no purchases and 2 sales.
Most recently, on 12 February 2024, the filings show a transaction in ImmunoGen, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations